



Imugene allowed Israel patent for cancer vaccine

- **Israeli Patent Office has issued an Intention to Grant Communication for Imugene's patent application protecting its cancer vaccine "HER-Vaxx"**
- **Patent will protect specific cancer vaccine formulations of commercial interest**

Melbourne, 24 March 2014: Australian biopharmaceutical company Imugene Limited (ASX:IMU) has received notice that the Israeli Patent Office has issued an Intention to Grant for the Company's proprietary cancer vaccine HER-Vaxx (Patent no. IL 194162, 2027 expiry).

HER-Vaxx is a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the \$US6.9 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer.

Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year.

Contact :

Paul A Hopper
Executive Chairman
+1 858 334 5820 (US)
+61 406 671 515 (Australia)
receptogen[at]earthlink.net

Dr Nick Ede
Executive Director
+61 400 642 254
nede[at]imugene.com

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology company developing clinical cancer vaccines to advance cancer care. The Company's lead product is HER-Vaxx, a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com